Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-1664 in advanced solid tumors
NCT06232408Phase 1Terminated
- Sponsor
- Repare Therapeutics
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of RP-1664 in solid tumor (advanced stage), sponsored by Repare Therapeutics. Primary endpoints: Treatment Related Treatment-Emergent Adverse Events with ≥3 CTCAE Grade up to 18 months and Dose Limiting Toxicities. Started Feb 2024; status: terminated.
02
Drugs
RP-1664
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06232408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232408.